Syndax Pharmaceuticals (STU:1T3) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1T3 Syndax Pharmaceuticals Inc STU:1T3
47 GF Score
Price €17.41
GF Value €728.36
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Syndax Pharmaceuticals  (STU:1T3) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 28.11 29.45

Syndax Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.97 24.98 29.45 28.85 23.72

STU:1T3 vs FTRE, KARD, STOK: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:1T3
47GF Score
Syndax Pharmaceuticals Inc STU:1T3
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Syndax Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Syndax Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.71/333.9520*333.9520
=0.710

Current CPI (Jun. 2026) = 333.9520.

Syndax Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.015 241.428 0.021
201612 0.016 241.432 0.022
201703 0.016 243.801 0.022
201706 0.014 244.955 0.019
201709 0.012 246.819 0.016
201712 0.042 246.524 0.057
201803 0.013 249.554 0.017
201806 0.013 251.989 0.017
201809 0.013 252.439 0.017
201812 0.012 251.233 0.016
201903 0.012 254.202 0.016
201906 0.011 256.143 0.014
201909 0.011 256.759 0.014
201912 0.011 256.974 0.014
202003 0.010 258.115 0.013
202006 0.008 257.797 0.010
202009 0.007 260.280 0.009
202012 0.007 260.474 0.009
202103 0.006 264.877 0.008
202106 0.006 271.696 0.007
202109 0.202 274.310 0.246
202112 1.885 278.802 2.258
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.038 314.175 0.040
202409 0.132 315.301 0.140
202412 0.085 315.605 0.090
202503 0.215 319.799 0.225
202506 0.381 322.561 0.394
202509 0.451 324.800 0.464
202512 0.675 324.054 0.696
202603 0.636 330.213 0.643
202606 0.710 333.952 0.710

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Syndax Pharmaceuticals (STU:1T3) Overvalued in 2026?

Based on GuruFocus' analysis, Syndax Pharmaceuticals stock appears to be undervalued. The current stock price of €17.41 is trading 97.6% below its estimated GF Value™ of €728.36. GuruFocus considers Syndax Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:1T3:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €728.36 vs. price of €17.41 (97.6% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the STU:1T3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
47GF Score

Get the complete analysis for STU:1T3

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.41
Price
€728.36
GF Value